Business Wire

Panasonic Develops High-Power Blue WBC Technology to Revolutionize DDL Applications on Microfabrication

Share

On January 29, 2020, Panasonic Corporation announced it has succeeded in demonstrating the world's highest brightness blue laser. This has been achieved by using the wavelength beam combining (WBC) technology [1] on a direct diode laser (DDL) to produce a high quality output beam [2]. With this technology, power scaling is enabled while maintaining the beam quality by simply increasing the number of laser sources. This demonstration opens the door to laser intensities that could be two orders of magnitude higher than conventional blue laser systems. This technology will contribute to the emerging microfabrication processes, whose demand is expected to grow in industrial applications, such as in the automotive industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005907/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wavelength Beam Combining (WBC) technology (Graphic: Business Wire)

The automotive industry is moving towards “electrification” and “miniaturization” while requiring “high rigidity,” “design flexibility” and “productivity.” Against this background, the anticipation for the microfabrication lasers that can process various kinds of materials such as copper, gold and plastic is building up. Especially, blue laser with a high optical absorption efficiency has a high demand in the field of copper fabrication for the automotive motors and batteries. Highly-productive processing requires a laser beam source that has both high output power and high beam quality.

In order to attain such a beam source, Panasonic started collaboration with TeraDiode, Inc. (TDI), a Massachusetts, U.S.-based company, in 2013, and since has been developing WBC technology which can combine multiple and different wavelengths into one combined beam. In 2014, Panasonic released LAPRISS; the world’s first laser welding robot system equipped with an infrared DDL using WBC technology*1. In 2017, the company acquired TDI as a wholly owned subsidiary*2 and started developing on the output-power optimization on WBC as well as shortening the wavelength.

The output power optimization of the high-beam-quality blue laser (wavelength band = 400 – 450nm) was realized by combining more than 100 emitters from multiple diode bars [3] with WBC technology.

This WBC technology combines the beams from multiple emitters at different wavelengths that are incident on the diffraction grating at angles corresponding to each wavelength. The resonator is then formed in between the shared partially-transparent mirror and each edge face of the emitters. As a result, the output beam has achieved a output of 135 W with a high beam quality of BPP [4] 1.5mm・mrad.

Going forward, Panasonic will develop a processing system that is equipped with this laser beam source, as well as the process optimization in laser processing.

Panasonic will hold exhibits and lecture sessions on our technical achievement at PHOTONICS WEST 2020 in San Francisco from February 1 to 6, 2020.*3

A part of this research and development includes the data obtained from a project – “Development of advanced laser processing with intelligence based on high-brightness and high-efficiency laser technologies (TACMI project)” – commissioned by the New Energy and Industrial Technology Development Organization (NEDO) of Japan.

[Applications] Laser processing (welding, cutting, etc.)

[Patents] Total of 571 patents both domestic and international (including pending applications)

Notes:
*1: Panasonic Corporation Topics
April 15th, 2014: Panasonic has Released a Laser Welding Robot System "LAPRISS"-Equipped with the world's first high-power direct diode laser
https://news.panasonic.com/jp/topics/2014/38440.html (In Japanese)
*2: Panasonic Corporation News Release
January 6th, 2017: Panasonic Acquires All Shares of U.S.-Based Industrial Laser Start-up TeraDiode, Inc.
https://news.panasonic.com/global/press/data/2017/01/en170106-3/en170106-3.html
*3: PHOTONICS WEST 2020, San Francisco, 1-6 February 2020

Glossary
[1] Wavelength Beam Combining (WBC) technology: The technology that combines the beams with different wavelengths that are emitted from the multiple DDLs (direct diode lasers) on a diffraction grating.

[2] Beam quality: An index indicates how easy it is to combine the beam. Higher beam quality has smaller diameter and highly collimate feature.

[3] Diode bar: A laser bar that has multiple emittance stripes (emitters) in an array configuration on a single semiconductor chip.

[4] BPP (Beam Parameter Products): This is defined as the product of the radius r0 of the beam waist at the focusing position multiplied by the half-value half-width θ of the beam divergence angle; BPP = r0xθ. The unit is expressed in [mm・mrad]. The smaller BPP is, the higher the beam quality becomes.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2020/01/en200129-2/en200129-2.html

Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww

TeraDiode, Inc.
https://www.teradiode.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Manufacturing Innovation Division
Promotion & Engineering Planning Department
Panasonic Corporation
Email: midpress@ml.jp.panasonic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye